Search
Flosequinan
go.drugbank.com/drugs/DB13228ApprovedWithdrawnFlosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]
Categories: Vasodilators Used in Cardiac DiseasesHesperidin
go.drugbank.com/drugs/DB04703ApprovedInvestigationalHesperidin is a flavan-on glycoside found in citrus fruits.
Mixtures: NAImatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalImatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. … Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".
Products: IMATINIB AL 100 MG FTA, IMATINIB AL 400 MG FTATideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawnIt is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.
Synonyms: 4-BENZYL-2-(A-NAPHTYL)-1,2,4-THIADIAZOLIDINE-3,5-DIONEVutrisiran
go.drugbank.com/drugs/DB16699ApprovedInvestigational[L42065] This siRNA therapeutic is indicated for the treatment of neuropathies associated with hereditary transthyretin-mediated amyloidosis (ATTR), a condition caused by mutations in the TTR gene. … [L34490,L42065] Vutrisiran is commercially available as a conjugate of N-acetylgalactosamine (GalNAc), a residue that enables the delivery of siRNA to hepatocytes.
Vernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalIntravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.
Pefloxacin
go.drugbank.com/drugs/DB00487ApprovedA synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.
Categories: Topoisomerase II InhibitorsPyrantel
go.drugbank.com/drugs/DB11156ApprovedVet approvedPyrantel is mainly available in formulations for dogs and cats as the embonate salt, containing a 34.7% pyrantel base [L1900]. … Pyrantel has shown to be effective after a single dose [L1905]. In humans, it is administered as pyrantel pamoate [A32282],[A32283],[L1893],[L1898].
Products: PIREL® SUSPENSION AL 5%, Pin-XDelandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigational[L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein. … of a muscle-specific promoter (MHCK7) to enhance expression in cardiac and skeletal muscles.
Vilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigational[L45839] In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support … Vilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity.